Abstract:Background: Treatment-resistant depression (TRD) is considered one of the major clinical challenges in the field of psychiatry. An estimated 44% of patients with major depressive disorder (MDD) do not respond to two consecutive antidepressant therapies, and 33% do not respond to up to four antidepressants. Over 15% of all patients with MDD remain refractory to any treatment intervention. rTMS is considered a treatment option for patients with TRD. Likewise, iCBT is evidence-based, symptom-focused psychotherapy recommended for the treatment of TRD. Objective: This study aimed to evaluate the initial comparative clinical effectiveness of rTMS treatment with and without iCBT as an innovative intervention for the treatment of participants diagnosed with TRD. Methods: This study is a prospective two-arm randomized controlled trial. Overall, 78 participants diagnosed with TRD were randomized to one of two treatment interventions: rTMS sessions alone and rTMS sessions plus iCBT. Participants in each group were made to complete evaluation measures at baseline, and 6 weeks (discharge) from treatment. The primary outcome measure was baseline to six weeks change in mean score for the 17-item Hamilton depression rating scale (HAMD-17). Secondary outcomes included mean baseline to six-week changes in the Columbia suicide severity rating scale (CSSRS) for the rate of suicidal ideations, the QIDS-SR16 for subjective depression, and the EQ-5D-5L to assess the quality of health in participants. Results: A majority of the participants were females 50 (64.1%), aged ≥ 40 39 (50.0%), and had college/university education 54 (73.0%). After adjusting for the baseline scores, the study failed to find a significant difference in the changes in mean scores for participants from baseline to six weeks between the two interventions under study on the HAMD-17 scale: F (1, 53) = 0.15, p = 0.70, partial eta squared = 0.003, CSSRS; F (1, 56) = 0.04 p = 0.85, partial eta squared = 0.001, QIDS-SR16 scale; F (1, 53) = 0.04 p = 0.61, partial eta squared = 0.005, and EQ-5D-VAS; F (1, 51) = 0.46 p = 0.50, and partial eta squared = 0.009. However, there was a significant reduction in means scores at week six compared to baseline scores for the combined study population on the HAMD-17 scale (42%), CSSRS (41%), QIDS-SR16 scale (35%), and EQ-VAS scale (62%). Conclusion: This study did not find that combined treatment of TRD with rTMS + iCBT (unguided) was superior to treatment with rTMS alone. Our findings do not support the use of combined treatment of rTMS + iCBT for the management of TRD disorders.

Lamotrigine Therapy for Bipolar Depression: Analysis of Self-Reported Patient Data

Efficacy of Quetiapine Monotherapy and Combination Therapy for Patients with Bipolar Depression with Mixed Features: A Randomized Controlled Pilot Study

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

Apparent Lack of Benefit of Combining Repetitive Transcranial Magnetic Stimulation with Internet-Delivered Cognitive Behavior Therapy for the Treatment of Resistant Depression: Patient-Centered Randomized Controlled Pilot Trial

The efficacy of lamotrigine in bipolar disorder: A systematic review and meta‐analysis

Lurasidone Versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study

The Impact of Quetiapine Monotherapy or in Combination with Lithium on the Thyroid Function in Patients with Bipolar Depression: A Retrospective Study

A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lamotrigine in the Maintenance Treatment of Chinese Adult Patients with Bipolar I Disorder

Efficacy of Repetitive Transcranial Magnetic Stimulation with Quetiapine in Treating Bipolar II Depression: a Randomized, Double-Blinded, Control Study

Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder

Effect of Lamotrigine on Quality of Life in Patients with Newly Diagnosed Epilepsy

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

Repetitive Transcranial Magnetic Stimulation In Combination With Citalopram In Young Patients With First-Episode Major Depressive Disorder: A Double-Blind, Randomized, Sham-Controlled Trial

An open-labeled, randomized comparative study of lamotrigine and lithium in treatment of bipolar depression

Acute neural effects of the mood stabiliser lamotrigine on emotional processing in healthy volunteers: a randomised control trial

Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)

P.2.e.029 Levetiracetam in the Management of Bipolar Depression: a Randomized, Double-Blind, Placebo Controlled Trial

A Statistical Analysis Plan for a Randomized Clinical Trial to Evaluate the Efficacy and Safety of Ethosuximide in Patients with Treatment-Resistant Depression.

Lamotrigine and Lithium Combination for Treatment of Rapid Cycling Bipolar Disorder: Results From Meta-Analysis

Lamotrigine in mood disorders: Flash survey on prescribing habits and blood tests practices

Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram